The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus for patients with metastatic renal cell carcinoma (mRCC) refractory to anti-VEGF therapy: Preliminary results of a pooled analysis of noninterventional studies.
Laurence Albiges
Consultant or Advisory Role - Astellas Pharma; Novartis; Pfizer
Honoraria - Novartis
Research Funding - Novartis
Lothar Bergmann
Honoraria - Novartis
Jean-Christophe Eymard
Honoraria - Novartis; Sanofi
Manuela Schmidinger
Consultant or Advisory Role - Astellas Pharma; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - Astellas Pharma; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Pfizer; Roche
Expert Testimony - Pfizer (U)
Aristotelis Bamias
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - Bayer; GlaxoSmithKline; Novartis
Research Funding - GlaxoSmithKline; Pfizer; Roche
Meryem Ktiouet
Employment or Leadership Position - Novartis
Gregor Fischer
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Despoina Xanthaki
Employment or Leadership Position - Novartis
Gernot Guderian
Employment or Leadership Position - Novartis